JA
Last reporting period 30 Jun, 2024
Updated 19 Sep, 2024
Last price
—
Market cap $B
6.889
Exchange
XNAS - Nasdaq
2 B
Last period Cash and equivalents ,USD
124%
Cash and equivalents has increased in 5 years
What is Cash and equivalents ?
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
See also Jazz Pharmaceuticals
Company Analysis
JAZZ valuation, rating, competitors, insights and company profile
Eyestock Rating
JAZZ financial analysis by Eyestock methodology
Valuation
JAZZ valuation using historical relative method
Statements
JAZZ Income Statements, Balance Sheet and Cash Flow Statements
Dividends
JAZZ dividend yield and annual dividend
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
Jazz Pharmaceuticals`s Cash and equivalents for the period ended 2024-06-30 are 2 B USD
